Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$20.22
-HK$0.68(-3.17%)
At close: 4:00 PM EDT
HK$20.22
-HK$0.68(-3.17%)
Day’s Range― - ―
52-Week RangeHK$18.76 - HK$35.34
Previous CloseN/A
Volume2.14M
Average Volume (3M)5.91M
Market Cap
HK$21.60B
Enterprise ValueHK$24.84K
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Sep 02, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$38.70Price Target Upside91.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.15B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA sustained step-up in revenue (≈61% in 2025) signals improving commercial traction for the company’s surgical-robotics platforms. Durable top-line expansion over multiple quarters supports scaling benefits, channel expansion and longer-term opportunity to convert fixed R&D into recurring revenue.
Gross MarginA positive gross margin (~29%) indicates underlying unit economics that can support profitability as volumes grow. With platform sales plus consumables/services, stable gross margins create a path to operating leverage and sustainable margins as manufacturing and service scale.
Improved LeverageMeaningful reduction in debt-to-equity reduces financial risk and interest burden, improving liquidity flexibility. Lower leverage enhances capacity for strategic investments or partnerships while reducing refinancing risk over the medium term as the business seeks operating break-even.
Bears Say
Continued Net LossesDeep negative net margins (~-45%) reflect structural unprofitability that erodes retained earnings and constrains reinvestment. Until operating profitability is achieved, the company will face persistent pressure on equity and limited ability to self-fund growth without external capital.
Negative Cash GenerationRecurring negative operating and free cash flow means the business relies on external financing to sustain operations. This creates dilution or refinancing risk, limits strategic optionality, and can constrain long-term R&D or commercialization unless cash generation turns positive.
Capital Base PressureDeclining equity and a deeply negative ROE (~-59%) signal capital erosion that weakens balance sheet resilience. This limits ability to take on cyclical shocks or pursue large hospital rollouts, and may raise cost of capital or debt covenants until profitability and retained earnings are restored.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$18.76 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$21.60B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 28 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.162 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.162.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.162 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. focuses on the comprehensive research, development, design, production, and distribution of surgical robotic systems, catering to markets in China and Europe. Their innovative product range features Toumai, a versatile laparoscopic surgical robot employed in urologic, gynecologic, thoracic, and general surgeries. They also provide DFVision, a 3D electronic laparoscope designed to improve visualization during abdominal, thoracic, and pelvic operations. For orthopedic procedures, the Honghu robot aids in knee and hip joint replacements, while the R-One system is specifically engineered for vascular interventions like coronary angioplasty. The iSR'obot, known as the Mona Lisa robotic system, specializes in transperineal prostate biopsies. Additionally, the company's offerings extend to specialized robots for spinal procedures, trans-bronchial diagnosis and treatment, TAVR (Transcatheter Aortic Valve Replacement), and automated needle-targeting systems for precise percutaneous lung biopsies and nephrolithotomy. Founded in 2014 and headquartered in Shanghai, China, the company functions as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$38.70
▲(91.37% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―